RPG LIFE SCIENCES LIMITED

RPG Life Sciences Carves Out API Business, Secures ₹243 Crore PE Backing to Build Integrated Pharma Platform

- RPG Life Sciences completed a slump sale of its API business to wholly owned subsidiary RPG Active Pharma Limited for ₹33.55 crore, effective August 15, 2026. - Healthcare private equity firm InvAscent will invest up to ₹243 crore initially, with an aggregate commitment of up to ₹700 crore in tranches to fund organic and inorganic growth. - RPG Active Pharma is acquiring Raghava Life Sciences' API business for up to ₹135 crore, adding 22 commercialized APIs and 7 development-stage assets. - The restructuring positions the API segment as a third growth engine alongside formulations, targeting backward integration and improved gross margins.